Learning Objectives: Participants should be able to: after completing this program

Examine the prognostic factors, staging, and diagnosis of breast cancer.
Describe the many forms of gynecological cancer.
Explain the fundamental biological and pharmacological concepts used in the diagnosis, management, and therapy of cancer.
Create all-inclusive care and treatment programs for genitourinary cancers, which include malignancies of the germ cells and bladder, prostate, other urothelial, and renal cancers.
Showcase the use of medicine to treat mesothelioma, lung, and thymic cancer.
Integrate ethical and medical modalities, taking into account challenges with treatment, side effects, supportive care, survivor experience, psychological effects of cancer, bioethical/legal/economic concerns, and communication abilities.
Accreditation Statement: Under the combined sponsorship of PeerPoint Medical Education Institute and American Physician Institute for Advanced Professional Studies, LLC, this program has been designed and carried out in compliance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME). The ACCME has accredited PeerPoint Medical Education Institute to provide continuing medical education for doctors.

MOC Accreditation Statement: The American Board of Internal Medicine’s (ABIM®) Maintenance of Certification (MOC) program allows participants to earn up to 34.25 MOC points upon successful completion of this CME activity. In accordance with the number of CME credits requested for the activity, participants will receive MOC points. In order for ACCME to award ABIM® MOC points, it is the CME activity provider’s duty to submit participant completion data.

Declaration of Designation: Virtual Course V4.1, Launch Date: October 15, 2017, End Date: October 14, 2020:
This continuing education is approved for a maximum of 34.25 AMA PRA Category 1 CreditsTM by the PeerPoint Medical Education Institute. Doctors should only submit credit claims that are appropriate for the level of their involvement in the activity.

Question Bank, April 1, 2018 Release Date; April 1, 2021 Termination Date:
This continuing education is approved for a maximum of 41.75 AMA PRA Category 1 CreditsTM by the PeerPoint Medical Education Institute. Doctors should only submit credit claims that are appropriate for the level of their involvement in the activity.

Nurses and Nurse Practitioners: The ANCC will accept AMA PRA Category 1 CreditsTM from institutions accredited by the ACCME toward fulfilling all of your Continuing Education requirements for recertification.

Physician Assistants: AMA PRA Category 1 CreditsTM from ACCME-accredited institutions are accepted by the NCCPA.

LASER-FOCUSED LECTURES: You will swiftly and simply become proficient with the ABIM® test material by taking the Pass Machine Medical Oncology board review course. This course includes an extensive collection of condensed video lectures that are well matched to the outline of the Medical Oncology Certification and Medical Oncology MOC exams. In this manner, you’ll concentrate on every exam topic and keyword without wasting any time.

The Question-Based Learning (or “QBL”) method guarantees that the material you examine is entirely pertinent to the ABIM® Medical Oncology exam. This tried-and-true technique allows you to examine a topic before answering a multiple-choice question by combining it with relevant lectures.

EXPERIENCED BOARD FACILTY: Board-certified instructors with experience teaching medical oncology board exam preparation teach the Medical Oncology Certification and Medical Oncology MOC courses. Every lecture is therefore completely board-relevant, current, and accurate from a medical standpoint.

Speaker/Topics: Hematologic Neoplasms
Myelodysplasia and Acute Leukemia (1 Hour)
Dr. Peter Silberstein
Myeloproliferative neoplasms and chronic myeloid leukemia (.75 hour)
Dr. Peter Silberstein
Leukemias that are Chronic Lymphoproliferative (.75 Hour)
Dr. Peter Silberstein
Lymphoma Hodgkin (.25 Hour)
Dr. Peter Silberstein
Multiple Myeloma with Dyscrasias of the Plasma Cell (.75 Hour)
Dr. Peter Silberstein
Lymphoma Non-Hodgkin (1.5 Hours)
Dr. Peter Silberstein
Cancer of the Thorax
Lung cancer with non-small cells (3.25 hours)
MD Sridhar Mani
Small Cell Lung Cancer (.25 Hour)
MD Sridhar Mani
Mesothelioma and Thymus Cancer (.25 Hour)
MD Sridhar Mani
Breast Cancer Premalignant Conditions and High-Risk Factors (.25 Hour)
Dr. Lea Baer
In Situ Carcinoma (.25 Hour)
Dr. Lea Baer
1.75 hours for early-stage invasive carcinoma
Dr. Lea Baer
Inflammatory and locally progressed illness (.25 Hour)
Dr. Lea Baer
Disease With Local Recurrence (.25 Hour)
Dr. Lea Baer
Disease Metastasis (1.5 Hours)
Dr. Lea Baer
Clinical Scenarios with Less Common Histologies (.25 Hour)
Dr. Lea Baer
Cancer of the Genitourinary System
Tumors of Germ Cells (.25 Hour)
Dr. Terence Friedlander
1.75 hours of prostate cancer
Dr. Terence Friedlander
One-hour Renal Cell Cancer
Dr. Terence Friedlander
Cancers of the uterus and other gastrointestinal tract (1 hour)
Dr. Terence Friedlander
Cancer of the Cervix, Vulva, and Vagina (Gynecologic Cancer;.25 Hour)
Dr. Peter Silberstein
Primary Peritoneal, Fallopian Tube, and Ovarian Cancers (1 Hour)
Dr. Peter Silberstein
Additional Gynecologic Cancers (0.25 Hour)
Dr. Peter Silberstein
Intestinal Cancer
Colorectal Cancer – Gastrointestinal (1 Hour)
Michael Morse, M.D.
Cancer of the Gastrointestinal System: Esophageal and Gastric (1 Hour)
Michael Morse, M.D.
Gastrointestinal – Hepatocellular and Biliary Gallbladder Cancer and Neuroendocrine Tumors (1 Hour)
Michael Morse, M.D.
Anal, Pancreatic, and Gastrointestinal Cancer (1 Hour)
Michael Morse, M.D.
Skin Cancer, Sarcomas, and Unknown Primary Site
Melanoma (.25 Hour)
Dr. Natalya Mar
Other Skin Cancers (.25 Hour)
Dr. Natalya Mar
Bone and Soft-Tissue Sarcomas (.25 Hour)
Natalya Mar, MD
Unknown Primary Site (1.25 Hours)
Natalya Mar, MD
Anticancer Therapeutics, Clinical Research Methodology, and Ethics
Principles of Allied Disciplines (.25 Hour)
MD Sridhar Mani
Anticancer Therapeutics (3 Hours)
MD Sridhar Mani
Clinical Research Methodology and Ethics (.25 Hour)
MD Sridhar Mani
Supportive Care, Survivorship, and Communication
Clinical Manifestations of advanced cancer and its treatment (1.5 Hours)
Dr. Peter Silberstein
Cancer Pain (.75 Hour)
Dr. Peter Silberstein
Survivorship Issues (.25 Hour)
Dr. Peter Silberstein
End of Life Issues (.75 Hour)
Dr. Peter Silberstein
Procedure-related issues (.25 Hour)
Dr. Peter Silberstein
Communication (.25 Hour)
Dr. Peter Silberstein
Head, Neck, Thyroid, and Central Nervous System Malignancies
Head and Neck Cancer, Thyroid Cancer, Salivary Gland (1 Hour)
Tanguy Seiwert, MD
Genetics and Tumor Biology
Cancer Biology and Genetics (.5 Hour)
MD Sridhar Mani